IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update


- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial -

See the rest here:
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

Related Posts